276678-35-4

Basic information

• Product Name: Pyrrolidine, 1-(4-bromo-2-methylbenzoyl)-
• Synonyms: 1-(4-bromo-2-methylbenzoyl)-pyrrolidine;(4-bromo-2-methyl-phenyl)-pyrrolidin-1-yl-methanone;3-methyl-4-(pyrrolidin-1-carbonyl)-bromobenzene;N-(4-bromo-2-methyl-benzoyl)pyrrolidine;1-[(4-bromo-2-methylphenyl)carbonyl]pyrrolidine;3-methyl-4-(pyrrolidin-1-yl-carbonyl)-bromobenzene
• CAS NO: 276678-35-4
• Molecular Formula: C12H14BrNO
• Molecular Weight: 268.153
• Mol File: 276678-35-4.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: Pyrrolidine, 1-(4-bromo-2-methylbenzoyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: Pyrrolidine, 1-(4-bromo-2-methylbenzoyl)-(276678-35-4)
• EPA Substance Registry System: Pyrrolidine, 1-(4-bromo-2-methylbenzoyl)-(276678-35-4)

Safety Data

• Hazardous Substances Data: 276678-35-4(Hazardous Substances Data)

Upstream product

• 123-75-1 pyrrolidine 
• 68837-59-2 4-bromo-2-methylbenzoic acid 
• 125700-67-6 O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate 
• 7087-68-5 N-ethyl-N,N-diisopropylamine 
• 5543-27-1 4-(pyrrolidinocarbonyl)phenyl bromide 
• 823-96-1 Trimethylboroxine 
• 21900-45-8 4-bromo-2-methylbenzoyl chloride 

Downstream Products

• 1092563-41-1 (2-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)(pyrrolidin-1-yl)methanone 
• 276675-59-3 4-[3-(3-methyl-4-pyrrolidinocarbonyl-phenyl)-propargylamino]pyridine 

Relevant articles and documents

SYNTHESIS, CRYSTAL STRUCTURE, AND DFT STUDY OF METHYL 3-FLUORO-5-(4,4,5,5-TETRAMETHYL-1,3,2- DIOXABOROLAN-2-YL)BENZOATE AND (2-METHYL-4- (4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL) PHENYL)(PYRROLIDIN-1-YL)METHANONE COMPOUNDS

Abstract: Methyl 3-fluoro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate and (2-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)(pyrrolidin-1-yl)methanone are boric acid ester intermediates with benzene rings. In this paper, the titl

CYCLOALKYL NITRILE PYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS

Compounds of formula I are provided, which are JAK inhibitors and are useful for the treatment of JAK-mediated diseases such as rheumatoid arthritis, asthma, COPD and cancer.

QUINOXALINE DERIVATIVES AS INHIBITORS OF THE TYROSINE KINASE ACTIVITY OF JANUS KINASES

The present invention relates to quinoxaline compound of the formula (I): wherein R1 is carbocyclyl or heterocyclyl, either of which is optionally substituted with 1, 2, 3, 4 or 5 R7; R2 is carbocyclyl or heterocyclyl, either of which is optionally substituted with 1, 2, 3, 4 or 5 R8; R3, R4, R5 and R6 are each independently hydrogen or R9; and R7, R8 and R9 are each independently selected from organic and inorganic substituents, their use in therapy of diseases, in particular diseases mediated by the tyrosine kinase activity of Janus kinases, including JAK-2 and JAK-3 kinases